Regeneron’s (REGN) treatment of lipodystrophy, mibavademab, was granted FDA orphan designation, according to a post on the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab
- 3 Best Value Stocks to Buy Now, 2/27/2025, According to Analysts
- REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc.
- Regeneron announces FDA accepted for review BLA for odronextamab
- Promising Developments and Strategic Positioning Justify Buy Rating for Regeneron